Dolutegravir

Dolutegravir, sold under the brand names Tivicay and Tivicay PD, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth. Common side effects include trouble sleeping, feeling tired, diarrhea, high blood sugar, and headache. Severe side effects may include allergic reactions and liver problems. It is unclear if use during breastfeeding is safe. Dolutegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication. Dolutegravir was approved for medical use in the United States in 2013. It is on the World Health Organization's List of Essential Medicines. Single tablet regimen combination drugs containing dolutegravir, such as dolutegravir/rilpivirine, dolutegravir/lamivudine, and abacavir/dolutegravir/lamivudine, are also available. As of 2019, the World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all persons with HIV.